142 related articles for article (PubMed ID: 2419418)
1. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response.
Mukherji B; Wilhelm SA; Guha A; Ergin MT
J Immunol; 1986 Mar; 136(5):1888-92. PubMed ID: 2419418
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression.
Mukherji B; Nashed AL; Guha A; Ergin MT
J Immunol; 1986 Mar; 136(5):1893-8. PubMed ID: 2419419
[TBL] [Abstract][Full Text] [Related]
3. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response.
Chakraborty NG; Twardzik DR; Sivanandham M; Ergin MT; Hellstrom KE; Mukherji B
J Immunol; 1990 Oct; 145(7):2359-64. PubMed ID: 1975829
[TBL] [Abstract][Full Text] [Related]
4. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
5. Cell-mediated amplification and down regulation of cytotoxic immune response against autologous human cancer.
Mukherji B; Guha A; Loomis R; Ergin MT
J Immunol; 1987 Mar; 138(6):1987-91. PubMed ID: 2950174
[TBL] [Abstract][Full Text] [Related]
6. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.
Mukherji B; Guha A; Chakraborty NG; Sivanandham M; Nashed AL; Sporn JR; Ergin MT
J Exp Med; 1989 Jun; 169(6):1961-76. PubMed ID: 2471770
[TBL] [Abstract][Full Text] [Related]
7. Suppressor cell activity in melanoma-draining lymph nodes.
Hoon DS; Bowker RJ; Cochran AJ
Cancer Res; 1987 Mar; 47(6):1529-33. PubMed ID: 2949828
[TBL] [Abstract][Full Text] [Related]
8. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
[TBL] [Abstract][Full Text] [Related]
9. Characterization of human cytotoxic lymphocytes directed against cells infected with typhus group rickettsiae: evidence for lymphokine activation of effectors.
Carl M; Dasch GA
J Immunol; 1986 Apr; 136(7):2654-61. PubMed ID: 3081648
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of human T cell subsets defined by monoclonal antibodies. VI. Distinct and opposing immunoregulatory functions within the OKT8+ population.
Thomas Y; Rogozinski L; Rabbani L; Chess A; Goldstein G; Chess L
J Mol Cell Immunol; 1984; 1(2):103-13. PubMed ID: 6152892
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
12. Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patients.
Mantovani G; Serri FG; Macciò A; Castelli P; Benedetti P; Scambia G; Santus S; Paderi R; Murtas MG; Ferreli A
Cancer Detect Prev; 1989; 13(5-6):323-32. PubMed ID: 2743354
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous and antibody-dependent cellular cytotoxicity in melanoma patients and healthy control presons.
Peter HH; Knoop F; Kalden JR
Z Immunitatsforsch Exp Klin Immunol; 1976 Apr; 151(3):263-81. PubMed ID: 134545
[TBL] [Abstract][Full Text] [Related]
14. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
15. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
16. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
17. [Autologous mixed lymphocyte culture (AMLC)].
Volk HD; Grunow R
Allerg Immunol (Leipz); 1984; 30(2):60-73. PubMed ID: 6237558
[TBL] [Abstract][Full Text] [Related]
18. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer.
Letessier EM; Sacchi M; Johnson JT; Herberman RB; Whiteside TL
Cell Immunol; 1990 Oct; 130(2):446-58. PubMed ID: 2145080
[TBL] [Abstract][Full Text] [Related]
19. Phorbol esters inhibit the functional activation of cytotoxic precursors in mixed lymphocyte cultures.
Masucci MG; Torsteinsdottir S; Pear W; Carstensen A; Klein E
J Immunol; 1984 Oct; 133(4):1755-62. PubMed ID: 6236256
[TBL] [Abstract][Full Text] [Related]
20. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
